H. Mukai

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi et al. · Supportive Care in Cancer · 2009 · 198 citations

Pharmacy, Oncology, Pharmacology +17

Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors

Kenji Kawada, Koji Murakami, Tatsuo Sato et al. · Japanese Journal of Clinical Oncology · 2006 · 31 citations

Medicine, Oncology, Pharmacology +17

Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors

Ken Nakagawa, Haruka Minami, Mineo Kanezaki et al. · Japanese Journal of Clinical Oncology · 2008 · 24 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase I study of GW572016 in patients with solid tumors

Hironobu Minami, Katsuhiro Nakagawa, Kenji Kawada et al. · Journal of Clinical Oncology · 2004 · 21 citations

Pharmacy, Oncology, Pharmacology +16

Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer.

H. Iwata, K. Aogi, Norikazu Masuda et al. · Journal of Clinical Oncology · 2010 · 20 citations

Medicine, Oncology, Pharmacology +17